866-997-4948(US-Canada Toll Free)

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Published By :

Transparency Market Research

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 150 Pages

Glaucoma Therapeutics Market: Overview 

Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma starts with topical eye drops belonging to the class of prostaglandins, beta blockers, alpha agonist, combined medication, carbonic anhydrase inhibitor and cholinergic. Administration of these eye drops reduces the production of the fluid inside eyes thereby reducing the intraocular pressure. Using topical eye drops is an alternative for surgery or delays the surgical procedure. This report analyzes the current and future prospects of the glaucoma therapeutics market based on type of drug class, end user and geography.

Glaucoma Therapeutics Market: Scope and Methodology

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major glaucoma therapeutics market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for each by drug class, end user, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each product was calculated by considering number of products used in the procedures and their market demand as per their use, number of product launched, average cost of products of each sub segment, trends in industry, end user trend, and adoption rate across all the geographies. The revenue generated for drug class was calculated on the basis of prevalence of diseases, and number of people affected by the disease

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on drug class, end-user, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the glaucoma therapeutics market in the current and future scenario.

Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The study also covers detailed country analysis contributing majorly in the glaucoma therapeutics market.

Glaucoma Therapeutics Market: Competitive Landscape

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the glaucoma therapeutics market are Allergan Inc., Merck & Co., Pfizer Inc., Novartis AG., Santen Pharmaceuticals, Valeant Pharmaceuticals and Aerie Pharmaceuticals.

The glaucoma therapeutics market has been segmented as follows:

Glaucoma Therapeutics Market, by Drug Class

  • Alpha Agonist
  • Beta Blockers
  • Prostaglandin Analogs
  • Carbonic Anhydrase Inhibitor
  • Cholinergic
  • Combined Medication

Glaucoma Therapeutics Market, by End Users

  • Ophthalmic clinic
  • Hospitals
  • Ambulatory Surgical Centers

Glaucoma Therapeutics Market, by Geography

  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Europe
  • U.K.
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • India
  • Japan
  • China
  • Australia
  • New Zealand
  • Rest of Asia Pacific
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • A.E.
  • Rest of MEA

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Glaucoma Therapeutics Market 

4. Market Overview
4.1. Introduction
4.1.1. Class of Drug Definition
4.1.2. Industry Evolution / Developments
4.2.Overview
4.3. Key Market Indicators
4.3.1. Region/Country Specific
4.3.2. Target Market Specific – Global Scenario
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.4.4. Trends 
4.5. Global Glaucoma Therapeutics MarketAnalysis and Forecasts, 2014–2024
4.5.1. Market Volume Projections, 2014–2024
4.5.2. Pricing- Actuals and Projections, 2014–2024
4.5.3. Market Revenue Projections (US$ Mn)
4.6. Global Glaucoma Therapeutics Market- Global Supply Demand Scenario
4.7. Porter’s Five Force Analysis
4.8. Value Chain Analysis
4.9. Market Outlook

5. Global Glaucoma Therapeutics MarketAnalysis and Forecasts, By Class of Drug 
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market ValueForecast By Class of Drug , 2014–2024
5.4.1. Prostaglandins
5.4.2. Alpha Agonist 
5.4.3. Beta Blockers
5.4.4. Carbonic Anhydrase Inhibitor 
5.4.5. Cholinergic 
5.4.6. Combined Medication
5.5. Class of DrugComparison Matrix
5.6. Market Attractiveness By Class of Drug 

6. Global Glaucoma Therapeutics MarketAnalysis and Forecasts, By End Users 
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market ValueForecast By End Users , 2014–2024
6.4.1. Ophthalmic Clinic
6.4.2. Hospitals 
6.4.3. Ambulatory Surgical Centers 
6.5. End UsersComparison Matrix
6.6. Market Attractiveness By End Users 

7. Global Glaucoma Therapeutics MarketAnalysis and Forecasts, By Region
7.1. Key Findings
7.2. Policies and Regulations
7.3. Market ValueForecast By Region
7.3.1. North America 
7.3.2. Europe 
7.3.3. Asia Pacific 
7.3.4. Latin America
7.3.5. Middle East & Africa 
7.4. Market Attractiveness By Country/Region

8. North America Global Glaucoma Therapeutics MarketAnalysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.1.2. Policies and Regulations
8.1.3. Price Trend Analysis
8.1.4. Key Trends
8.2. Market ValueForecast By Class of Drug , 2014–2024
8.2.1. Prostaglandins
8.2.2. Alpha Agonist 
8.2.3. Beta Blockers
8.2.4. Carbonic Anhydrase Inhibitor 
8.2.5. Cholinergic 
8.2.6. Combined Medication
8.3. Market ValueForecast By End Users , 2014–2024
8.3.1. Ophthalmic Clinic
8.3.2. Hospitals 
8.3.3. Ambulatory Surgical Centers 
8.4. Market ValueForecast By Country , 2014–2024
8.4.1. U.S.
8.4.2. Canada
8.5. Market Attractiveness Analysis 
8.5.1. By Class of Drug 
8.5.2. By End Users 
8.5.3. By Country

9. Europe Global Glaucoma Therapeutics MarketAnalysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Policies and Regulations
9.1.3. Price Trend Analysis
9.1.4. Key Trends
9.2. Market ValueForecast By Class of Drug , 2014–2024
9.2.1. Prostaglandins
9.2.2. Alpha Agonist 
9.2.3. Beta Blockers
9.2.4. Carbonic Anhydrase Inhibitor 
9.2.5. Cholinergic 
9.2.6. Combined Medication
9.3. Market ValueForecast By End Users , 2014–2024
9.3.1. Ophthalmic Clinic
9.3.2. Hospitals 
9.3.3. Ambulatory Surgical Centers 
9.4. Market ValueForecast By Country , 2014–2024
9.4.1. Germany
9.4.2. U.K.
9.4.3. France
9.4.4. Spain
9.4.5. Italy
9.4.6. Rest of Europe 
9.5. Market Attractiveness Analysis 
9.5.1. By Class of Drug 
9.5.2. By End Users 
9.5.3. By Country

10. Asia Pacific Global Glaucoma Therapeutics MarketAnalysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Price Trend Analysis
10.1.4. Key Trends
10.2. Market ValueForecast By Class of Drug , 2014–2024
10.2.1. Prostaglandins
10.2.2. Alpha Agonist 
10.2.3. Beta Blockers
10.2.4. Carbonic Anhydrase Inhibitor 
10.2.5. Cholinergic 
10.2.6. Combined Medication
10.3. Market ValueForecast By End Users , 2014–2024
10.3.1. Ophthalmic Clinic
10.3.2. Hospitals 
10.3.3. Ambulatory Surgical Centers 
10.4. Market ValueForecast By Country , 2014–2024
10.4.1. Japan
10.4.2. China
10.4.3. Australia
10.4.4. New Zealand
10.4.5. India
10.4.6. Rest of Asia Pacific
10.5. Market Attractiveness Analysis 
10.5.1. By Class of Drug 
10.5.2. By End Users 
10.5.3. By Country

11. Latin AmericaGlobal Glaucoma Therapeutics MarketAnalysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Policies and Regulations
11.1.3. Price Trend Analysis
11.1.4. Key Trends
11.2. Market ValueForecast By Class of Drug , 2014–2024
11.2.1. Prostaglandins
11.2.2. Alpha Agonist 
11.2.3. Beta Blockers
11.2.4. Carbonic Anhydrase Inhibitor 
11.2.5. Cholinergic 
11.2.6. Combined Medication
11.3. Market ValueForecast By End Users , 2014–2024
11.3.1. Ophthalmic Clinic
11.3.2. Hospitals 
11.3.3. Ambulatory Surgical Centers 
11.4. Market ValueForecast By Country , 2014–2024
11.4.1. Brazil
11.4.2. Mexico
11.5. Market Attractiveness Analysis 
11.5.1. By Class of Drug 
11.5.2. By End Users 
11.5.3. By Country

12. Middle East & Africa Global Glaucoma Therapeutics MarketAnalysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Policies and Regulations
12.1.3. Price Trend Analysis
12.1.4. Key Trends
12.2. Market ValueForecast By Class of Drug , 2014–2024
12.2.1. Prostaglandins
12.2.2. Alpha Agonist 
12.2.3. Beta Blockers
12.2.4. Carbonic Anhydrase Inhibitor 
12.2.5. Cholinergic 
12.2.6. Combined Medication
12.3. Market ValueForecast By End Users , 2014–2024
12.3.1. Ophthalmic Clinic
12.3.2. Hospitals 
12.3.3. Ambulatory Surgical Centers 
12.4. Market ValueForecast By Country , 2014–2024
12.4.1. South Africa
12.4.2. UAE
12.4.3. Saudi Arabia
12.5. Market Attractiveness Analysis 
12.5.1. By Class of Drug 
12.5.2. By End Users 
12.5.3. By Country

13. Competition Landscape
13.1. Market Player – Competition Matrix (By Tier and Size of companies)
13.2. Market Share Analysis By Company (2015)
13.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
13.3.1. Allergan Inc.
13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.1.2. Financial Overview
13.3.1.3. Product Portfolio
13.3.1.4. SWOT Analysis
13.3.1.5. Strategic Overview
13.3.2. Merck & Co.
13.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
13.3.2.2. Financial Overview
13.3.2.3. Product Portfolio
13.3.2.4. SWOT Analysis 
13.3.2.5. Strategic Overview
13.3.3. Novartis AG
13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.3.2. Financial Overview
13.3.3.3. Product Portfolio
13.3.3.4. SWOT Analysis 
13.3.3.5. Strategic Overview
13.3.4. Pfizer Inc. 
13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.4.2. Financial Overview
13.3.4.3. Product Portfolio
13.3.4.4. SWOT Analysis 
13.3.4.5. Strategic Overview
13.3.5. Santen Pharmaceuticals
13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.5.2. Financial Overview
13.3.5.3. Product Portfolio
13.3.5.4. SWOT Analysis 
13.3.5.5. Strategic Overview
13.3.6. Valeant Pharmaceuticals Inc.
13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.6.2. Financial Overview
13.3.6.3. Product Portfolio
13.3.6.4. SWOT Analysis 
13.3.6.5. Strategic Overview 
13.3.7. Aerie Pharmaceuticals Inc.
13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.7.2. Financial Overview
13.3.7.3. Product Portfolio
13.3.7.4. SWOT Analysis 
13.3.7.5. Strategic Overview

List of Table

Table 1 Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 2 Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 3 Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 4 North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 5 North America Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 6 North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 7 Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 8 Europe Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 9 Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 10 Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 11 Asia Pacific Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 12 Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 14 Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 15 Latin America Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 16 Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 17 Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 18 Middle East & Africa Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 19 Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024

List of Chart

Figure 1: Market Value Share, by Drug Class (2016) Revenue (US$ Mn)
Figure 2: Market Value Share, by End-user (2016) Revenue (US$ Mn)
Figure 3: Market Value Share, by Region (2016) Revenue (US$ Mn)
Figure 4: Global Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 5: Global Prostaglandins Market Revenue (US$ Mn), 2014–2024
Figure 6: Global Beta Blockers Market Revenue (US$ Mn), 2014–2024
Figure 7: Global Alpha Agonist Market, Revenue (US$ Mn), 2014–2024
Figure 8: Global Carbonic Anhydrase Inhibitor Market, Revenue (US$ Mn), 2014–2024
Figure 9: Global Combined Medication Market, Revenue (US$ Mn), 2014–2024
Figure 10: Global Cholinergic Market, Revenue (US$ Mn), 2014–2024
Figure 11: Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 12: Global Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2015 and 2024
Figure 13: Global Hospital Market Revenue (US$ Mn), 2014–2024
Figure 14: Global Ophthalmic Clinics Market Revenue (US$ Mn), 2014–2024
Figure 15: Global Ambulatory Surgical Centers Market Revenue (US$ Mn), 2014–2024
Figure 16: Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2015
Figure 17: Global Glaucoma Therapeutics Market Value Share Analysis, by Region, 2015 and 2024
Figure 18: Glaucoma Therapeutics Market Attractiveness Analysis, by Region, 2015
Figure 19: North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 20: North America Glaucoma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 21: North America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 22: North America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2015 and 2024
Figure 23: North America Glaucoma Therapeutics Market by Country, 2015 and 2024
Figure 24: North America Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 25: North America Glaucoma Therapeutics Market Attractiveness Analysis, by End User, 2015
Figure 26: Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure 27: Europe Glaucoma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 28: Europe Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 29: Europe Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2015 and 2024
Figure 30: Europe Glaucoma Therapeutics Market by Country, 2015 and 2024
Figure 31: Europe Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 32: Europe Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2015
Figure 33: Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 34: Asia Pacific Glaucoma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 35: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 36: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2015 and 2024
Figure 37: Asia Pacific Glaucoma Therapeutics Market by Country, 2015 and 2024
Figure 38: Asia Pacific Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 39: Asia Pacific Glaucoma Therapeutics Market Attractiveness Analysis, by End User, 2015
Figure 40: Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 41: Latin America Glaucoma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 42: Latin America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 43: Latin America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2015 and 2024
Figure 44: North America Glaucoma Therapeutics Market by Country, 2015 and 2024
Figure 45: Latin America Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 46: Latin America Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2015
Figure 47: Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure 48: Middle East & Africa Glaucoma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 49: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 50: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2015 and 2024
Figure 51: Middle East & Africa Glaucoma Therapeutics Market by Country, 2015 and 2024
Figure 52: Middle East & Africa Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 53: Middle East & Africa Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2015
Figure 54: Global Glaucoma Therapeutics Market Share Analysis, by Company (2015)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *